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Production of high-titer helper-free retroviruses by
transient transfection
(retroviral packaing cells/gene therapy)
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Rockefeiler University, Box 161, 1230 York Avenue, New York, NY 10021
Contributed by David Baltimore, May 27, 1993
ABSTRACT The generation of high-titer, helper-free ret-
roviruses by transient transection has been achieved by using
the highy transfectable 293T cell line into which are stably
introduced constructs that express retroviral packaging func-
tions. The resulting ecotropic virus packing cell line BOSC
23 produces infectious retrovirus at >106 infectious units/ml
of supernatant within 72 hr after CaPO4-mediated btansfec-
tion. A stringent assay for replication-competent virus showed
that no helper virus was present. The system can produce high
titers of retroviral vectors expressing genes that are extremely
difficult to propagate at high titer in stable producer lines. This
method should facilitate and extend the use of helper-free
retroviral gene transfer, as weli as be useful for gene therapy.
Present methods for creating high-titer, helper-free retroviral
stocks employ the creation of a stable producer cell line that
expresses the retroviral vector (1). Producer lines are made
by introducing the retroviral vector into a packaging cell line,
which synthesizes all the proteins required for viral assem-
bly. It is then necessary to screen many clones for one clone
that expresses the retroviral vector at high titer, because
virus production by the original pool of transfected clones is
low. Selection takes at least 1 month, and prolonged high
expression of the retroviral mRNA may slow the growth of
the producer line, allowing outgrowth of poorly producing
variants during prolonged cultivation.
To circumvent these problems, a strategy was devised that
uses transient transfection ofthe retroviral packaging cell line
BOSC 23 to produce high-titer, helper-free infectious retro-
viruses. The BOSC 23 producer cell line (derived from the
Ad5-transformed human embryonic kidney 293 cell line) is
more transfectable than the currently employed packaging
cell lines. By using BOSC 23 packaging cells and optimizing
the CaPO4 transfection procedure, we have obtained retro-
viral titers in excess of 107 infectious particles per milliliter of
supernatant within 48-72 hr after transfection. The retrovi-
ruses produced are helper-free and can infect early hemato-
poietic progenitors. Moreover, titers in excess of 106 have
routinely been attained by using retroviral vectors expressing
genes that appear toxic to stable producer lines.
MATERIALS AND METHODS
Celi Lines and Plasmids. 293T cells (2), originally referred
to as 293tsA1609neo, were obtained from S. Haase (Stanford
University) and grown in Dulbecco's modified Eagle's me-
dium containing 1)o (vol/vol) fetal calf serum (FCS). Drug
selections in transfected 293T cells were done at 400 pg of
hygromycin (Calbiochem) per ml for hygromycin resistance
and 50 ug of mycophenolic acid (Sigma) per ml for guanine
phosphoribosyltransferase (gpt) resistance. The following
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cell lines, all grown in Dulbecco's modified Eagle's medium
containing 10%o (vol/vol) calf serum were used: NIH 3T3,
BAG (3), N54 (4), and 210W (5).
The following plasmids, all grown in Escherichia coli
DH5a, were used: pBND 8 [D. Turner and C. Cepko,
personal communication; a retroviral vector derived from the
BAG vector (3) in which (B-galactosidase (3-gal) expression is
directed by the viral promoter in the long terminal repeat and
the neomycin resistance cassette is deleted], pCRIPenv- (6),
pCRIPgag-2 (6), MFG-lacZ (7), MFG-tPA [similar to MFG-
lacZ, but expressing the human tissue plasminogen activator
gene in place of (-gal (7)], pZAP (8), pSV2Hgm (9), pGPT2E
(10), pGD (11), pGDv-abi (12), and pGD210bcr/abl (11).
Enzymatic Assays and Nudeic Acid Prdures. Staining for
(3-gal activity in intact cells and spleen was performed as
described (13). Reverse transcriptase (RT) activity was as-
sayed in the culture medium ofexponentially growing cells as
described by Goff et al. (14). The in vitro abl kinase assays
were performed as described by Konopka et al. (15) using
anti-pEX4 as the immunoprecipitating antibody. Isolation of
DNA and blot analysis was performed by standard proce-
dures (16).
Transfections, Infections, and Determination ofViral Titers.
Except where noted, all transfections were done on 60-mm
dishes where 1.5-2.5 x 106 293T cells (or derivatives) were
plated in 4 ml of 10%o FCS the night prior to transfection.
Where indicated, chloroquine was added to this medium to a
final concentration of 25 IAM ~5 min prior to adding the
DNA/Hepes buffered saline solution. Either 250 or 500 p1 of
Hepes buffered saline solution (pH 7.05) was added to an
equal volume of DNA/CaCl2 solution by bubbling, and the
resulting solution was immediately added to the above me-
dium (17). The cells were then returned to the 37°C incubator
(5% C02) for 24 hr. Subsequently, the medium was changed
to 3 ml offresh 10%o FCS, and 24-48 hr later, the medium was
removed and either filtered through a 0.45-,m filter or
centrifuged at 500 x g for 5 min in a Sorvall RT6000B
centrifuge. In experiments with chloroquine, the medium was
changed to 10% FCS at 10 hr posttransfection and changed a
second time at 24 hr posttransfection. Infections were per-
formed as described (6). Viral titer was determined as the
average number ofblue ((-gal-producing) cells per 10-25 high
power fields (40,000-100,000 total cells) multiplied by a
factor to account for magnification, plate size, and dilution of
the infectious stock. When fluorescence-activated cell sort-
ing (FACS) analysis was performed, the percentage of pos-
itive cells was multiplied by the total number of cells on the
dish. G418 selection was performed as above except that at
48 hr postinfection the cells were split 1:10 into selective
Abbreviations: (-gal, ,-galactosidase; G418R, G418 resistance; RT,
reverse transcriptase; FCS, fetal calf serum; FACS, fluorescence-
activated cell sorting; SV40, simian virus 40; gpt, guanine phospho-
ribosyltransferase.
*Present address: Department of Pharmacology; Stanford Univer-
sity School of Medicine, Stanford, CA 94305.
8392
Proc. Natl. Acad. Sci. USA 90 (1993) 8393
medium and refed every 3 days, and colonies were counted
12 days later. In determining the G418-resistance (G418R)
titer, the number of colonies was divided by 4 to account for
two cell doublings. v-abl focus-forming activity was assayed
by infecting NIH 3T3 cells with dilutions of BOSC 23-
produced v-abl retroviral supernatants as described (18).
Transformed colonies were counted 10 days after infection.
Hdper Virus Asy. One milliliter of supernatant from
transfected BOSC 23 cells was used to infect BAG cells as
described above, and the cells were split 1:10 every 3 or 4
days. To determine the titer of the virus used to infect the
BAG cells, 1 ml of the viral supernatant from the transfected
BOSC 23 cells was used in parallel to infect 3T3 cells, which
were assayed for j-gal or G418R. When passages 3, 5, and 10
ofthe BAG-infected cells had reached w50%o confluence, the
medium was changed, and 24 hr later, 3 ml of this supernatant
was filtered (0.45 uM) and used to infect 3T3 cells, which
were stained for (-gal 48 hr later. To test for the generation
of helper virus after cotransfection of the plasmids encoding
the packaging constructs, 5 jg of pCRIPenv-, pCRIPgag-2,
and pBND 8 were cotransfected into 293T/17 cells, and 1 ml
of viral supernatant was used to infect the BAG cells. The
BAG cells were treated as above except that (-gal staining
was performed on passage 3 cells only.
Dome Marrow ra atat . Bone marrow transplant
was performed as described (11). Recipients were 6- to
8-week-old female BALB/c mice, and 6- to 8-week-old male
BALB/c mice treated with 2 mg of5-fluorouracil 5 days prior
to bone marrow harvest were donors. Cocultivation was done
in WEHI-3B-conditioned medium with BOSC 23 cells that
had been transfected with 6 pg of MFG-lacZ prior to cocul-
tivation. Nonadherent cells were removed 48 hr later and
injected into the lateral tail vein of recipient mice that had
received 900 cGy (two doses separated by 3 hr) at cell
numbers rangingfrom 20,000 to 100,000 per mouse. Surviving
mice were sacrificed at day 13, and the spleens were ana-
lyzed.
RESULTS
Production of high-titer retroviral stocks by transient trans-
fection appears to be limited by the transfectability of the
producer cells, the type ofexpression construct, and the copy
numberofthe introduced construct. Previous studies showed
that the AdS-transformed embryonic kidney cell line 293 (19)
is more transfectable than NIH 3T3 cells, the cell line from
which most producer cell lines have been derived (G.P.N.,
unpublished data). As a result, it seemed that transient
transfection of a packaging line based on 293 cells might
produce high-titer retroviral stocks. To maximize our
chances of transiently obtaining such stocks, we built our
system from the 293T line, a 293 subline that contains the
simn virus 40 (SV40) large tumor antigen (2). Although
expression of SV40 large tumor antigen may increase the
replication of vectors containing the SV40 origin of replica-
tion, this aspect of the 293T line was not investigated in the
current studies.
Selecdt of a Hlh-Producer Sublne. We initially investi-
gated whether it was possible to obtain high-titer retroviral
stocks by transient transfection of 293T cells in the presence
of helper virus. As a first step, the 293T cell line was cloned
by limiting dilution to ensure that the starting population was
uniform. Fourteen independent clones were screened by
transfecting a replication-defective retroviral construct con-
taining the lacZ gene (pBND 8; D. Tumer and C. Cepko,
personal communication). Cells from each clone were his-
tochemically stained to detect the lacZ gene product. Greater
than 50% of the cells from 9 clones and from the parental
population expressed (3-gal at 48 hrposttransfection, whereas
<25% of cells from the 5 remaining clones stained positive
(W.S.P., unpublished data).
To determine which clone was capable of producing the
highest titer infectious retroviral stock, seven of the nine
highly transfectable clones were cotransfected with equimo-
lar amounts (3 ,ug) of pBND 8 and a clone of replication-
competent Moloney murine leukemia virus [pZAP (8)]. After
infection of NIH 3T3 cells and staining for (-gal activity,
three clones gave the highest titer of =1.5 x 106. One ofthese
clones (subsequently referred to as 293T/17) was chosen for
further analysis. In subsequent experiments, we were able to
obtain a retroviral titer of 4.6 x 106 after transfecting 2 x 106
293T/17 cells with 7.5 pg of both pBND 8 and pZAP (Table
1).
Creation of the BOSC 23 Producer Line. To create a
helper-free producer cell line, two plasmids, pCRIPenv- and
pCRIPgag-2, that encode the Moloney packaging functions
were sequentially transfected into 293/17 cells (6) (Fig. 1).
pCRIPenv- contains a mutation in the envelope region and
expresses both gag and pol products (6). pCRIPgag-2 con-
tains mutations in the gag region and expresses only the
ecotropic envelope (6). In addition, both plasmids were
deleted for the packaging site, and the 3' long-terminal repeat
was replaced by an SV40 poly(A) site (6). With these multiple
changes, more than two crossover events are required for the
generation of helper virus, even with the use of vectors
containing packaging sites extending into gag, such as MFG
(6). To create the helper-free packaging cell line, it was
decided to introduce the pCRIPenv- and pCRIPgag-2 con-
structs one after the other, rather than simultaneously, to
decrease the risk of recombination and production of repli-
cation-competent virus (6).
Table 1. Retroviral production from BOSC 23 and progenitor
cells after transfection
Cell line
(passage no.) Construct CQN* Titert Help*
293T/17 7.5 pg pBND - 4.6 x 106 +
7.5 pg pZAP
293T/17 5 pg pBND - 1.1 x 105 +
S-pg pCRIPgag-2
S pg pCRIPenv-
ANJOU 65 3.5p&gpBND - 0
ANJOU 65 3.5 pg pBND - 1.5 x 105
3.5 pg pCRIPgag-2
BARTLETT 3 pg pBND - 1.6 x 106
96 (2)
BARTLETT 3pgpBND - 6 x 10
96 (8)
BOSC 23 (2) 3 pg MFG-lacZ - 2.9 x 106
BOSC 23 (6) 3 pg MFG-lacZ + 8.6 x 106
BOSC 23 (12)§ 6 pg MFG-lacZl +1 1.5 x 107
BOSC 23 (12)11 3 pg MFG-lacZ - 6.5 x 106
BOSC 23 (6) 3 Ag pGD + 3.9 x 106** -
BOSC 23 (6) 3 pg pGDvabl + 2.9 x 106** -
BOSC 23 (6) 3 Ag pGD210tb/abl + 1.1 x 106**
BOSC 23 (6) 3 pug MFG-tPAtt + -
Presence (+) or absence (-) of 25 pM chloroquine as described in
the text.
tlnfectious titer per milliliter (*-gal-positive cells).
*Presence (+) or absence (-) of replication-competent virus as
assayed in BAG cells (see Materials and Methods).§Sixty percent ofthe cells were transfected as assayed by FACS (see
Materials and Methods).¶Volume of all transfection reagents was doubled.
I'Thirty percent of the cells were transfected as assayed by FACS.
**Titers determined by neomycin resistance.
ttNot titered, but MFG-lacZ transfected in parallel had a titer of 7 x
106/ml.
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FiG. 1. Flow diagram outlining the creation of the BOSC 23
packaging cell line. Details are given in the text. *, Retrovirus titer
determined after transfecting 293T clones with a lacZ retrovirus and
helper virus; CaPO4, calcium phosphate-mediated transfection; t,
retrovirus titer determined after transfecting indicated cell line with
lacZretrovirus only; shaded cells, cells stably expressing the gag-pol
products of the pCRIPenv- plasmid; , cells stably expressing the
ecotropic envelope expressed from the pCRIPgag-2 plasmid.
The first step in creating the helper-free line was to create
a cell line expressing high levels of gag-pol. Six micrograms
ofAse I-linearized pCRIPenv- plasmid was transfected into
293T/17 cells together with 3 pug of a plasmid encoding
hygromycin as a selectable marker. Individual colonies,
grown in hygromycin selection medium, were picked and
screened for RT activity (14). Of 175 clones assayed, four
clones produced similar or greater amounts of RT than CRE
cells, a 3T3-derived producer cell line made by transfecting
the pCRIPenv and pCRIPgag-2 constructs (6). The best
gag-pol producing cell line, no. 65 (subsequently referred to
as ANJOU 65), produced RT at a level 10 times that ofCRE
and 1/10th that of wild type Moloney virus-infected cells
(Fig. 2). The RT activity ofANJOU 65 remained stable for at
least 15 passages, even when the cells were grown without
hygromycin selection. Transient cotransfection of ANJOU
65 cells with pBND 8 and the envelope-expressing construct,
pCRIPgag-2, gave a retroviral titer of 1.5 x 10 (Table 1).
The next step was to transfect the ecotropic envelope
construct and select a cell line producing the highest titer of
infectious retrovirus. ANJOU 65 cells were transfected with
10 pug of Ase I-linearized pCRIPgag-2 and 5 pg of pGPT2E,
a plasmid encoding the selectable marker gene for gpt resis-
tance (10). The cells were initially grown in gpt selection
ZAP 1/10 ZAP 1/100 ZAP
S.
3T3 ANJOU 65 CRE
S
ANJOU 47 ANJOU 205 ANJOU 96
FiG. 2. RT assays of supernatants from clones of ANJOU cells
transfected with pCRIPenv-. Individual clones resistant to hygro-
mycin were isolated and grown, and the presence of RT activity in
the medium was assayed by incubating 10 /4 of cell supernatant with
50 p1 of a reaction cocktail containing 50 mM Tris HCI (pH 8.3), 20
mM dithiothreitol, 0.6 mM MnCl2, 60 mM NaCl, 0.05% Nonidet
P40, 5 pg of oligodeoxythymidylic acid per ml, 10 pg ofpolyriboad-
enylic acid per ml, and 10 pM [a-32P]dTTP (specific activity, 1
Ci/mmol; 1 Ci = 37 GBq). The reaction was incubated for 1 hr at
3rC, spotted onto DE-81 paper (Whatman), washed, and autora-
diographed (14). Positive controls are supernatant from 293T/17 cells
transfected with pZAP [wild-type Moloney virus, (8)] and superna-
tant from CRE cells (6). The supernatants from the pZAP-transfected
cells were diluted 1:10 and 1:100 as indicated. NIH 3T3 supernatant
is included as a negative control.
medium (20), but once individual clones reached sufficient
density to be grown on 10-cm plates, selection was removed
and they were screened as described in Materials and Meth-
ods. Of 70 clones screened, only one clone, no. 96 (subse-
quently referred to as BARTLETT 96), produced lacZ ret-
rovirus with a titer in excess of 106/ml following transfection
with pBND 8 (Table 1).
Because BARTLETT 96 and two subcloned lines all
demonstrated a decrease in the ability to package retrovirus
over time when grown without gpt selection (Table 1 and
W.S.P., unpublished data), it appeared that gpt selection
might be necessary for maintenance of the high-titer pheno-
type of this subline. To test this hypothesis, passage 2 cells
of the BARTLETT 96 line were thawed and cloned by
limiting dilution, either in the presence or absence of gpt
selection. For these experiments, MFG-lacZ, a f-gal-
expressing retroviral vector containing an extended retrovi-
rus RNA packaging site was used in the transfection assay
(7). After transfection ofthe BARTLETT 96 cells, this vector
produced infectious retroviral stocks with titers 2-fold
higher than pBND 8, which does not contain the extended
packaging site (W.S.P., unpublished data). Twenty-two
clones maintained in gpt selection medium were analyzed,
and 7 of these clones had titers greater than 106/ml. Of these
7 clones, the clone producing the highest titer, BOSC 23, gave
a titer of 2.9 x 106/ml (Table 1). BOSC 23, used in all
subsequent experiments, was maintained in gpt selective
medium, and its viral titer remained stable for at least 14
passages (Table 1).
Chloroquine Treatment of BOSC 23 Cells Doubles the
Infectious Titer. To maximize the infectious titer, several
modifications were made to the CaPO4 transfection protocol.
Growing the BOSC 23 line in 10%o FCS with 25 p,M chloro-
quine for the initial 10 hr of transfection resulted in a 2- to
3-fold increase in titer (Table 1). This is presumably due to the
lysozomal neutralizing activity of the chloroquine (16). Dou-
bling the volume of all transfection reagents also appeared to
result in a slightly higher transfection efficiency (Table 1).
The effects of chloroquine and reagent volume on infectious
titer appeared to be the result of increasing transfection
efficiency because changes in the percent ofcells transfected,
as measured by FACS, were nearly linear with viral titer
8394 Cell Biology: Pear et al.
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(Table 1; G.P.N. and W.S.P., unpublished data). Using these
conditions, we have been able to transfect as many as 60%o of
the BOSC 23 cells, and this has resulted in retroviral stocks
producing lacZ virus titers in the 107/ml range (Table 1).
Transent Transfecton of BOSC 23 Produces High-Titer
abl-Expressing Retroviral Vectors. One reason for creating the
BOSC 23 packaging line was to obtain high-titer retroviral
stocks transducing genes that may be difficult to obtain at high
titers from stably selected producer lines. Previous results in
this laboratory have shown that it is very difficult to maintain
either v-abl or P210bcr/ab1 helper-free retroviral producer cell
lines at titers greater than 105/ml (M.L.S. and W.S.P., un-
published data). To test whether our transient system was
capable of producing these recombinant retroviruses at a
higher titer, either pGDv-'bl (12) or pGD210bcr/abl (11) was
transfected into BOSC 23 cells. Resulting supernatants were
then titered by G418 selection for the neomycin-resistance
gene also contained in the retroviral vector (11). The parental
pGD vector (11), expressing only the neomycin-resistance
gene, produced a viral titer of 3.9 x 106/nml (Table 1). pGDv-11l
produced virus at a G418R titer of 2.9 x 106/ml (Table 1), and
pGD210bcr/abl produced virus at a G418R titer of 1.1 x 106/ml
(Table 1). To show that the abl gene was transduced as
efficiently as the G418R marker, we infected NIH 3T3 cells
with dilutions ofBOSC 23-produced pGDv-ab' retrovirus. This
gave a titer of 2.1 x 106 transformed foci per ml (Fig. 3A),
consistent with the titer determined by G418R. To demonstrate
that the correct abl protein product was made by the BOSC
23-produced retroviral stocks, in vitro abl kinase assays were
performed on the infected 3T3 cells (15). The P160vabl protein
immunoprecipitated Erom the pGDv-abLinfected cells was iden-
tical in size to the P160v-ab' from a cell line expressing Abelson
murine leukemia virus [N54 (4)] (Fig. 4A). Similarly, P210 was
immunoprecipitated from pGD210bcr/abl-infected 3T3 cells,
and the protein was identical in size to the P210 product ofthe
210W cell line (5), a cell line expressing P210b-cr/al (Fig. 4B).
Tests for Replication-Competent Virus. To test for the
production of replication-competent virus, the BAG indica-
tor cell line was used (3). This cell line contains an integrated
(-gal provirus capable ofbeing rescued by either helper virus
or retroviral packaging functions and is able to detect infec-
tious replication-competent retrovirus in 1 ml of supernatant
from a known retroviral producer line at dilutions up to 5 x
106/ml (W.S.P., unpublished data). BAG cells were infected
with 1 ml of viral supernatant from pGD (G418 titer: 3.9 x
106/ml), pGDv-abl (G418 titer: 2.9 x 106/ml), or MFG-tPA
(not titered; however, MFG-lacZ transfected in parallel had
a titer of 7 x 106/ml). Cells were split every 2-3 days at 1:10,
and 3 ml of supernatant was used to infect 3T3 cells after
passages 3, 5, and 10 of the BAG-infected cells. No /-gal-
FiG. 3. Morphologic transformation of 3T3 cells by BOSC 23-
produced v-abl. NIH 3T3 cells (5 x 105 cells plated the night before
infection) were infected with 1 ml ofundiluted 48-hr supernatant from
either pGDabl-transfected BOSC 23 cells (A) or pGD-transfected
BOSC 23 cells (B) as described in Materials and Methods. G418R
titers for these stocks were 2.9 x 106/ml (pGDv-abl) and 3.9 x 106/ml
(pGD). Corresponding focus-forming titers were 2.1 x 106/ml for the
pGDv-abl stock and <104/ml for the pGD stock. Photos were taken










FIG. 4. In vitro abl kinase activity following infection ofNIH 3T3
cells with supernatant from BOSC 23-produced P160V-abl retrovirus
or P210bcr/abl retrovirus. The P160v-abl (A) and P210bcr/abl (B) proteins
are indicated by arrows. Three micrograms of the retroviral vector
(pGDv-abl, pGD210br/abl, or pGD) was transfected into BOSC 23
cells in the presence of 25 ptM chloroquine as described in the text.
Forty-eight hours posttransfection, 1 ml ofthe supernatant was used
to infect NIH 3T3 cells, and 48 hr later, the cells were extracted and
precipitated with anti-abl antiserum (pEX4) as described in ref. 15.
Samples were fractionated by electrophoresis through a 7.5% SDS/
polyacrylamide gel, and the phosphorylated proteins were detected
by autoradiography for 12 hr with an intensifying screen. Prior to the
immunoprecipitations, protein concentrations were equal, except
that there was approximately half as much protein in the N54 cell
extract. (A) Lane 1, NIH 3T3 cells (negative control); lane 2,
pGDvabLinfected NIH 3T3 cells; lane 3, N54 cells (positive control)
(4). (B) Lane 1, pGD-infected NIH 3T3 cells (negative control); lane
2, pGD210b/abLinfected NIH 3T3 cells; lane 3, 210W cells (positive
control) (5). Size markers are 207, 111, and 71 kDa.
positive cells were observed upon infection of 3T3 cells with
supernatants derived from cells that had undergone 9, 15, and
30 rounds of replication (Table 1). As a positive control,
MFG-tPA and pZAP were cotransfected, and the supernatant
was able to rescue the provirus at all ofthe above time points.
To test the hypothesis that simultaneous introduction of
the two plasmids encoding the gag-pol and env functions
would produce replication-competent virus by recombina-
tion, pCRIPenv-, pCRIPgag-2, and pBND 8 were cotrans-
fected into 293T/17 cells, and 48 hr later, 1 ml of supernatant
was used to infect BAG cells. The BAG cells were split 1:10
for three passages, and 1 ml ofsupematant was used to infect
3T3 cells, which were stained for /-gal activity. l3-gal-positive
cells were present, indicating that cointroduction of these
three elements results in the formation of helper virus (Table
1).
Retroviral Vectors Produced by BOSC 23 Cels Are Capable
of Infectig Day 13 Colony-Forming Unit-Spleen. To show
that BOSC 23 cells transfected with a retroviral vector could
be used to infect hematopoietic progenitors, day 13 colony-
forming unit-spleen assays (21) were carried out by using
cocultivated murine bone marrow. Ficoll-banded cells (1.25
x 106) derived from mouse tibia were cocultured in WEHI-
3B-conditioned medium with BOSC 23 cells that had been
transfected 1 day previously with MFG-lacZ. Parallel exper-
iments showed that the MFG-lacZ-transfected cells produced
virus at a titer of 5 x 106/ml. Forty-eight hours later, the
nonadherent cells were washed off the adherent layer, and
20,000 cells were injected into each lethally irradiated recip-
ient. The animals were sacrificed 13 days after reconstitution,
and 20 distinct spleen colonies were dissected. DNA pre-
pared from each colony was cleaved with Xba I (which cuts
once in each retroviral long terminal repeat) and blotted to
nylon membranes. Hybridization with a /3-gal probe revealed
the expected 4.0-kb fragment in 10 out of 15 analyzable
colonies (W.S.P. and M.L.S., unpublished data).
Ceff Biology: Pear et al.
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DISCUSSION
A method for the rapid generation of high-titer stocks of
helper-free retroviruses is described. By introducing con-
structs expressing retroviral packaging functions into a sub-
clone of293T cells, a retroviral packaging cell line, BOSC 23,
was created. BOSC 23 cells are able to produce infectious
retroviral stocks with titers as high as 107 infectious particles
per ml within 72 hr after transfection and without selection.
Retroviral stocks of high titers are necessary for efficient
introduction of recombinant genetic material into rare cells,
such as stem cells and infrequently dividing cells such as
neurons, and to be able to infect all cells in a large target
population.
A major advantage of the BOSC 23 system is the ability to
produce high-titer retroviral stocks expressing genes that are
detrimental to the growth of stable producer cell lines. Stable
producer cell lines expressing either v-abl or P210bcr/ab1
retroviral vectors showed that even when these cell lines
initially expressed the retroviral constructs at high titer, the
titers fell with continued propagation of the cell line (M.L.S.
and W.S.P., unpublished data). Although this phenomenon is
not well understood, it may be due to mechanisms relating to
the degree of transformation and cellular adherence rather
than a direct toxic effect of the gene product (22). This
phenomenon is not limited to retroviral constructs containing
members of the abl family because we have seen a similar
phenomenon with members of the rel family of transcription
factors (M.L.S., unpublished data). Using the BOSC 23
system, titers in excess of 106/ml for both the abl- and
rel-related vectors have been achieved (M.L.S., unpublished
data). Because BOSC 23 cells are exposed to the retroviral
products for less than 72 hr, detrimental effects of the gene
product upon the producer cell line are minimized. The
finding that the pGDv-abl and pGDbcr/abl titers are lower than
those from the parental pGD vector suggests that there may
still be a toxic effect; however, even with this effect, the
resultant titers are >106/ml.
The BOSC 23 system is also free of detectable replication-
competent virus. This was demonstrated by the use of a
stringent assay in which either packaging of the helper
functions or production of helper virus itself would result in
the rescue ofthe integrated lacZ-containing provirus from the
BAG cells. No rescue was seen using three different retro-
viral constructs, including a vector containing an extended
retroviral RNA packaging site (MFG-tPA), even though each
BAG-infected population underwent at least 30 rounds of
replication.
There have been several previous attempts to make high-
titer retroviruses by transient transfection. Transient trans-
fection of either the Psi-2 or PA317 cell lines results in titers
in the 104/ml range (3, 23). Recently, Landau and Littman
(24) have described a system in which two retroviral vectors
containing SV40 ori sequences and expressing the packaging
functions from one vector and the gene of interest from the
other vector are cotransfected into COS cells. They have
obtained titers as high as 1 x 105, which appear helper free,
and are dependent on the amplification of the SV40 ori-
containing vectors. Although only one recombination event
is necessary to create replication-competent virus in their
system, they do not report the presence of helper virus (24).
Cotransfection of 293T/17 cells with pCRIPenv-, pCRIP-
gag-2, and pBND, which contain the same region of homol-
ogy as in the COS-based system but requires more than two
recombination events to generate helper virus, results in
replication-competent virus. While we would not have an-
ticipated the observed absence of helper virus in the COS-
based system, one possible explanation is that COS cells
recombine unintegrated DNA less frequently than 293 cells.
The BOSC 23 cell line should have many applications.
These include testing the efficacy of different retroviral
vectors and conditions, overexpressing proteins, and creat-
ing animal models of disease. The present work also suggests
that an amphotropic counterpart to the BOSC 23 cell line may
be useful in human gene therapy.
We thank Dr. Richard Mulligan and members of his laboratory for
many helpful discussions and for providing the CRIP, CRE, and
MFG constructs. We thank Dr. Steve Gofffor critical review of this
manuscript. We thank Dr. C. Cepko for pBND 8 and Dr. M. Jasin for
pGPT2E. W.S.P. was supported by a Howard Hughes Postdoctoral
Fellowship for Physicians. G.P.N. was supported by a grant from the
Leukemia Society ofAmerica. This work was supported by National
Institutes of Health Grant CA51462 to D.B.
1. Mulligan, R. C. (1993) Science 260, 926-932.
2. DuBridge, R. B., Tang, P., Hsia, H. C., Phaik-Mooi, L.,
Miller, J. H. & Calos, M. P. (1987) Mol. Cell. Biol. 7, 379-387.
3. Price, J., Turner, D. & Cepko, C. (1987) Proc. Natl. Acad. Sci.
USA 84, 156-160.
4. Jackson, P. & Baltimore, D. (1989) EMBO J. 8, 449-456.
5. Lugo, T. G. & Witte, 0. N. (1989) Mol. Cell. Biol. 9, 1263-
1270.
6. Danos, 0. & Mulligan, R. C. (1988) Proc. Natl. Acad. Sci. USA
85, 6460-6464.
7. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky,
H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. &
Mulligan, R. C. (1993) Proc. Natl. Acad. Sci. USA 90, 3539-
3543.
8. Shoemaker, C., Hoffmann, J., Goff, S. P. & Baltimore, D.
(1981) J. Virol. 40, 164-172.
9. Bernard, H. U., Krammer, G. & Rowekamp, W. G. (1985)
Exp. Cell Res. 158, 237-243.
10. Jasin, M. & Berg, P. (1988) Genes Dev. 2, 1353-1363.
11. Daley, G. Q., Van Etten, R. A. & Baltimore, D. (1990) Science
247, 824-830.
12. Scott, M. L., Van Etten, R. A., Daley, G. Q. & Baltimore, D.
(1991) Proc. Natl. Acad. Sci. USA 88, 6506-6510.
13. Nolan, G. P., Fiering, S., Nicolas, J. F. & Herzenberg, L. A.
(1988) Proc. Natl. Acad. Sci. USA 85, 2603-2607.
14. Goff, S., Traktman, P. & Baltimore, D. (1981) J. Virol. 38,
239-248.
15. Konopka, J. B. & Witte, 0. N. (1985) Mol. Cell. Biol. 5,
3116-3123.
16. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D.,
Seidman, J. G., Smith, J. A. & Struhl, K. (1989) Current
Protocols in Molecular Biology (Wiley, New York).
17. Heinzel, S. S., Krysan, P. J., Calos, M. P. & DuBridge, R. B.
(1988) J. Virol. 62, 3738-3746.
18. Scher, C. D. & Siegler, R. (1975) Nature (London) 253, 729-
731.
19. Graham, F. L., Smiley, J., Russell, W. C. & Naish, R. (1977)
J. Gen. Virol. 36, 59-72.
20. Mulligan, R. C. & Berg, P. (1981) Proc. Natl. Acad. Sci. USA
78, 2072-2076.
21. Spangrude, G. J. (1989) Immunol. Today 10, 344-350.
22. Ziegler, S. F., Whitlock, C. A., Goff, S. P., Gifford, A. &
Witte, 0. N. (1981) Cell 27, 477-486.
23. Miller, A. D., Trauber, D. R. & Buttimore, C. (1986) Som. Ce!!
Mol. Gen. 12, 175-183.
24. Landau, N. R. & Littman, D. R. (1992) J. Virol. 66, 5110-5113.
83% Ceff Biology: Pear et al.
